Equillium to Acquire Metacrine in All-Stock Transaction

Gryphon Investors Acquires Metagenics from Alticor

December 1, 2021

Consumer Products

Gryphon Investors signed a definitive agreement to acquire Metagenics, Inc. from Alticor, with the transaction expected to close in Q4 2021. WhiteHorse Capital provided a first-lien credit facility to Meta Buyer, LLC to support the acquisition; Gryphon will partner with Metagenics' management to invest in global growth, including potential strategic acquisitions.

Equillium Acquires Bioniz Therapeutics

February 16, 2022

Biotechnology

Equillium, Inc. (Nasdaq: EQ) acquired privately held Bioniz Therapeutics, obtaining exclusive worldwide rights to Bioniz's pipeline (BNZ-1, BNZ-2, BNZ-3) and proprietary discovery platform in an all-stock transaction (5,699,492 shares, ~19.3% of Equillium outstanding) plus up to $57.5M in development milestones and up to $250M in sales milestones. The acquisition expands Equillium's immunology capabilities and pipeline, adding complementary clinical-stage cytokine-targeting assets and key research and clinical personnel.

Revolution Medicines to Acquire EQRx in All-Stock Deal

August 1, 2023

Pharmaceuticals

Revolution Medicines (NASDAQ: RVMD) has agreed to acquire EQRx (NASDAQ: EQRX) in an all‑stock transaction that will transfer more than $1 billion in net cash to Revolution’s balance sheet. The deal is intended to strengthen Revolution Medicines’ financial position to accelerate clinical development of its RAS(ON) inhibitor pipeline while EQRx will wind down most of its R&D programs post-closing.

Chimerix Acquires Oncoceutics

January 7, 2021

Biotechnology

Chimerix (NASDAQ: CMRX) acquired clinical-stage Oncoceutics, gaining the late-stage oncology candidate ONC201 to expand its oncology pipeline. The deal closed January 7, 2021, for $78 million (half stock, half cash) plus potential milestones and royalties.

Biogen Acquires Alcyone Therapeutics

September 19, 2025

Medical Devices

Biogen has acquired Alcyone Therapeutics to obtain the ThecaFlex DRx intrathecal drug‑delivery system, integrating Alcyone employees into Biogen’s product delivery solutions team. Alcyone will receive $85 million upfront plus contingent milestone payments; Biogen will handle development, commercialization and manufacturing of ThecaFlex DRx while Alcyone’s remaining therapeutic assets are being divested into Neela Therapeutics.

Incyte Acquires Escient Pharmaceuticals

April 23, 2024

Biotechnology

Incyte has agreed to acquire Escient Pharmaceuticals for $750 million plus Escient's net cash, adding two first‑in‑class oral MRGPR antagonists (EP262 and EP547) to its inflammation and autoimmunity portfolio. The acquisition, subject to customary closing conditions and HSR clearance, expands Incyte's pipeline in dermatology, chronic urticaria and pruritus with expected closing in 3Q 2024.